CLINICAL TRIAL SUMMARY

MDACC Study No:2005-0048 (clinicaltrials.gov NCT No: NCT00129740)
Title:Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) with Oral Nilotinib
Principal Investigator:Jorge Cortes
Treatment Agent:AMN 107
Study Status:Open
Study Description:The goal of this clinical research study is to learn if an experimental agent,
AMN107 (nilotinib), can help to control CML in chronic phase. The safety of
this experimental agent will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:AMN 107
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:N/A
Supported By:N/A
Return Visit:Every 3-4 months for 1 year, then every 6-12 months.
Home Care:All therapy is self-administered.


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jorge Cortes
Dept:Leukemia
For Clinical Trial Enrollment:713-794-5783
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults